Oxford Cannabinoid Technologies
Oxford Cannabinoid Technologies is a UK-listed clinical-stage biopharmaceutical company developing cannabinoid-based medicines, with lead candidate OCT130401 entering Phase I trials for trigeminal neuralgia.
- Company typePublic
- Founded2017
- HeadquartersOxford, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Oxford Cannabinoid Technologies does
Oxford Cannabinoid Technologies Holdings PLC is a UK-domiciled, publicly listed (LSE: OCTP) clinical-stage biopharmaceutical company founded in 2017 and headquartered in Oxford, England. The company's stated mission is to combine cannabinoid medicine with world-class scientific research, and its disclosed lead asset is OCT130401, a proprietary cannabinoid-based drug candidate positioned for the treatment of trigeminal neuralgia, a severe neuropathic facial pain condition with limited existing therapeutic options.
OCT operates a single-asset, indication-focused R&D model. Its underlying technology is a cannabinoid-based pharmaceutical formulation, with the pipeline concentrated on OCT130401, which is advancing toward a Phase I clinical trial (expected to start in Q2 2024) at a site to be identified in Australia. The company does not disclose pricing, products on market, or commercial customers; the provided financials indicate no reported revenue across FY2021–FY2024, consistent with a pre-commercial posture. Capital has historically been raised through equity rounds (Kingsley Capital Partners in 2017, Casa Verde Capital in 2018) and, most recently, a February 2024 £565,000 convertible loan note with Cantheon Capital LLC alongside existing shareholders and directors to fund the Phase I program.
The company serves the eventual patients and prescribers in the trigeminal neuralgia and broader neuropathic pain space — a market projected to reach $1 billion by 2030 at a 6.4% CAGR — but currently has no paying customers. Leadership comprises CEO John Lucas, founder/co-founder Tarek Tabsh, Executive Chairman Neil Mahapatra, COO and General Counsel Clarissa Sowemimo-Coker, and CSO Valentino Parravicini. With 11–50 employees and a lean capital base, OCT's near-term value creation depends on clinical execution, regulatory milestones, and additional funding rounds.
Oxford Cannabinoid Technologies firmographics
Firmographics- Name
- Oxford Cannabinoid Technologies
- Legal name
- Oxford Cannabinoid Technologies Holdings PLC
- Website
- https://oxcantech.com
- Company type
- Public
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Oxford Cannabinoid Technologies is a UK-listed clinical-stage biopharmaceutical company developing cannabinoid-based medicines, with lead candidate OCT130401 entering Phase I trials for trigeminal neuralgia.
- Ownership category
- akta.pro rank
Oxford Cannabinoid Technologies industry classification
Industry- Product category
- Cannabinoid Pharmaceuticals
- NAICS
- Medicinal and Botanical Manufacturing (325411)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- Pain Relief & Anti-Inflammatory (Analgesics) (HLAIADAA)
Keywords
Where Oxford Cannabinoid Technologies is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Oxford Cannabinoid Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Oxford Cannabinoid Technologies product offering
Product offeringCore offering
Oxford Cannabinoid Technologies is a clinical-stage biopharmaceutical company developing cannabinoid-based prescription medicines. Its lead drug candidate, OCT130401, is being advanced through Phase I clinical trials for the treatment of trigeminal neuralgia, a severe neuropathic facial pain condition with limited existing therapeutic options.
Product overview
Oxford Cannabinoid Technologies is a biopharmaceutical company developing cannabinoid-based medicines. Its primary product candidate is OCT130401, a treatment for trigeminal neuralgia that has entered Phase I clinical trials. The company is funded through convertible loan agreements while advancing its clinical development program.
Differentiator
Problem solved
Functional benefit
Products and services
- OCT130401
Companies that use Oxford Cannabinoid Technologies
Customer profileIdeal customer profiles1 record
Oxford Cannabinoid Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Oxford Cannabinoid Technologies partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights4 records
Oxford Cannabinoid Technologies competitors and assessment
Company assessmentDirect peers
- Jazz Pharmaceuticals (GW Pharmaceuticals): Jazz acquired GW Pharmaceuticals, the originator of approved cannabinoid medicines Sativex and Epidiolex, and is the most direct comparable for OCT as a cannabinoid-based biopharma developing CNS/neuropathic pain therapies.
- Zynerba Pharmaceuticals: Clinical-stage developer of transdermal cannabinoid therapeutics for CNS and pain indications, with a comparable single-asset, indication-focused development model.
- Botanix Pharmaceuticals: Late-clinical-stage cannabinoid pharmaceutical company developing synthetic cannabinoid formulations, overlapping with OCT's botanical-derived cannabinoid drug development strategy.
- InMed Pharmaceuticals: Clinical-stage biopharmaceutical company developing cannabinoid-based therapeutics, including candidates in pain and CNS, with a comparable preclinical/early-clinical stage profile.
- Tetra Bio-Pharma: Developer of cannabinoid-derived prescription medicines and synthetic cannabinoid drug candidates, with parallel focus on pain and CNS indications.
Emerging players
- Emerald Health Pharmaceuticals: Clinical-stage company developing cannabinoid-derived small molecules for CNS and inflammatory conditions, with similar botanical-pharma translation model.
- Axim Biotechnologies: Developer of cannabinoid-based pharmaceutical products targeting pain, neurological, and inflammatory conditions, with comparable pipeline overlap.
- Skye Bioscience: Clinical-stage biopharma developing cannabinoid-derived therapeutics, sharing a botanical-cannabinoid drug development thesis with OCT.
Broad incumbents
- Pfizer (Lyrica/Pregabalin): Established CNS/neuropathic pain incumbent marketing Lyrica; defines the standard-of-care competitive backdrop for any new neuropathic pain entrant.
- Vertex Pharmaceuticals: Specialty CNS and pain biopharma developing next-generation neuropathic pain therapies, setting competitive benchmarks for efficacy and safety in the indication OCT is targeting.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Oxford Cannabinoid Technologies social profiles
Digital presenceOxford Cannabinoid Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oxford Cannabinoid Technologies leadership team
Management profileNumber of profiles
Profiles5 records
Oxford Cannabinoid Technologies funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oxford Cannabinoid Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oxford Cannabinoid Technologies
What does Oxford Cannabinoid Technologies do?
Oxford Cannabinoid Technologies is a clinical-stage biopharmaceutical company developing cannabinoid-based prescription medicines. Its lead drug candidate, OCT130401, is being advanced through Phase I clinical trials for the treatment of trigeminal neuralgia, a severe neuropathic facial pain condition with limited existing therapeutic options.
Is Oxford Cannabinoid Technologies a public or private company?
Oxford Cannabinoid Technologies is a public company. It is classified as public and is currently operating.
When was Oxford Cannabinoid Technologies founded?
Oxford Cannabinoid Technologies was founded in 2017. It employs 11 to 50 people.
Where is Oxford Cannabinoid Technologies based?
Oxford Cannabinoid Technologies is headquartered in Oxford, United Kingdom, in the Europe region.
Who are Oxford Cannabinoid Technologies's main competitors?
Direct peers on record are Jazz Pharmaceuticals (GW Pharmaceuticals), Zynerba Pharmaceuticals, Botanix Pharmaceuticals, InMed Pharmaceuticals and Tetra Bio-Pharma. Emerging players are Emerald Health Pharmaceuticals, Axim Biotechnologies and Skye Bioscience. Broad incumbents are Pfizer (Lyrica/Pregabalin) and Vertex Pharmaceuticals.
Does Oxford Cannabinoid Technologies have an API?
No public API is recorded for Oxford Cannabinoid Technologies.
What industry is Oxford Cannabinoid Technologies in?
Oxford Cannabinoid Technologies's product category is Cannabinoid Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIADAA, Pain Relief & Anti-Inflammatory (Analgesics). Its NAICS code is 325411 and its SIC code is 2833.